Meitheal Pharmaceuticals (Meitheal) is pleased to announce that we have launched Thiotepa for Injection, USP, in 15 mg per vial in a single-dose vial and 100 mg per vial in a single-dose vial.
Meitheal will offer Thiotepa for Injection, USP, in a pack of 1 vial for both presentations.
ABOUT THIOTEPA FOR INJECTION, USP
Thiotepa for Injection is an alkylating drug indicated:
- For treatment of adenocarcinoma of the breast or ovary.
- For controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities.
- For treatment of superficial papillary carcinoma of the urinary bladder.
For full prescribing information, please click on the following link.
Learn more about Thiotepa for Injection, USP
